Form 4: OKYO Pharma Director Acquires Shares

Bernard Denoyer, a Director at OKYO Pharma Ltd, acquired 3,500 shares through the exercise of options.

Summary

• Bernard Denoyer, a Director of OKYO Pharma Ltd, reported a transaction on June 8, 2026.
• He acquired 3,500 common shares by exercising options with an exercise price of $1.85 per share.
• These options were granted with a vesting schedule of 25% per year over four years, starting on the first anniversary of the grant date.
• Following this transaction, Denoyer beneficially owns 35,190 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction related to stock options rather than a significant strategic or financial event.

Positives

• Director Bernard Denoyer has increased his direct beneficial ownership of OKYO Pharma Ltd shares.
• The acquisition of shares through option exercise indicates a potential alignment of management interests with shareholder value.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Management Comments

• Options vest 25% per year over four years beginning on the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that insider transactions, such as this option exercise by a director, are common in the pharmaceutical sector as a way for executives to demonstrate confidence in the company's prospects and align their financial interests with shareholders.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of confidence in the company's future performance.

Key Dates

Keywords

OKYO Pharma Ltd, Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Director, Securities Exchange Act